Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on A...
18 May 2018 - 6:05AM
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the
upcoming presentation describing the broad potential for anti-FcRn
therapeutics and the discovery of M281. The presentation will be
part of the 11th International Congress on Autoimmunity taking
place in Lisbon, Portugal.
Presentation Details
Presentation Title:
Targeting the Neonatal Fc Receptor (FcRn) for the Treatment of
Pathogenic IgG Antibody DiseasesSession Title:
IVIG MIMETICS: Potential Next Generation Biologics in
Autoimmune Diseases Presentation Date/Time:
Saturday, May 19, 2018; 5:30 p.m. –5:50 p.m. WEST
Location: Auditorium VIII, Parallel
SessionPresenter: Anthony Manning, Ph.D., Senior
Vice President Research, Momenta Pharmaceuticals
The slides will be made available shortly after
the presentation on the Momenta Pharmaceuticals website at:
http://ir.momentapharma.com/events-and-presentations
The presentation will focus on a discussion of
the broad potential of FcRn antagonists in rare auto- and
allo-immune diseases, and describe details of the discovery and
development of M281, Momenta’s anti-FcRn therapeutic. The
presentation will highlight the unique design attributes of M281,
including best-in-class potency and pH insensitivity achieved via
proprietary somatic hypermutation technology, fully human IgG
scaffold to minimize immunogenic potential, and state-of-art
aglycosylation variant design to eliminate any effector function
potential. Dr. Manning will present X-ray crystallographic
data revealing a unique structural basis for best-in-class
affinity, extensive pre-clinical pharmacology and toxicology
evaluation, and Phase 1 human clinical trial data that support the
potential of M281 as a best-in-class FcRn antagonist.
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural and functional
analysis of complex drugs and is headquartered in Cambridge,
MA. Momenta is applying its technology to the development of
generic versions of complex drugs, biosimilar and potentially
interchangeable biologics, and to the discovery and development of
novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not
form a part of this press release. The company’s logo, trademarks,
and service marks are the property of Momenta Pharmaceuticals, Inc.
All other trade names, trademarks, or service marks are property of
their respective owners.
Investor Relations:Sarah CarmodyMomenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com
Media Relations:Karen SharmaMacDougall
Biomedical
Communications1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2024 to May 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From May 2023 to May 2024